Results 91 to 100 of about 527 (122)

Effect of Aficamten on Structure and Function in Patients with Obstructive Hypertrophic Cardiomyopathy: The FOREST-HCM CMR Sub-study

Journal of Cardiovascular Magnetic Resonance
Ahmad Masri, MD, Rhanderson Cardoso, MD, Theodore Abraham, MD, Lubna Choudhury, MD, Florian Rader, MD, Sara Saberi, MD, Albree Tower-Rader, MD, Andrew Wang, MD, Stephen Heitner, MD, Stuart Kupfer, MD, Fady Malik, MD, PhD, Chiara Melloni, MD, Jenny Wei, PhD, Amy Wohltman, Raymond Kwong, MD   +14 more
doaj   +1 more source

Complication management in hypertrophic cardiomyopathy. [PDF]

Heart Fail Rev
Höller V, Zwetsloot PP, Santner V, Schwegel N, Pötsch SL, Verheyen N, Michels M.   +6 more
europepmc   +1 more source

Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial. [PDF]

Circulation
Campain J, Griskowitz C, Newlands C, Claggett BL, Kulac IJ, McGinnis S, Giverts I, Moreno F, Minasian A, Prasad C, Rupert L, Landsteiner I, Iskenderian N, Coats CJ, Lee MMY, Maron MS, Owens AT, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Wohltman A, Malhotra R, Lewis GD.   +23 more
europepmc   +1 more source

Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: From Sarcomere to Clinic. [PDF]

Int J Mol Sci
Nakamura K, Okumura T, Kato S, Onoue K, Kubo T, Kouzu H, Yano T, Inomata T.   +7 more
europepmc   +1 more source

Septal reduction therapy in obstructive hypertrophic cardiomyopathy: contextualizing outcomes in an era of cardiac myosin inhibition. [PDF]

Eur Heart J Open
Govind A.
europepmc   +1 more source

RoMa Classification: When the Parts Do Not Equal the Sum. [PDF]

J Am Heart Assoc
MacNamara JP, Angadi SS.
europepmc   +1 more source

Cardiovascular pharmacotherapy in 2025. [PDF]

Eur Heart J Cardiovasc Pharmacother
Tamargo J, Agewall S, Ambrosio G, Borghi C, Cerbai E, Dan GA, Drexel H, Ferdinandy P, Grove EL, Klingenberg R, Morais J, Parker W, Rocca B, Sulzgruber P, Semb AG, Sossalla S, Kaski JC, Dobrev D.   +17 more
europepmc   +1 more source

Correction: Effect of Hepatic Impairment or Renal Impairment on the Pharmacokinetics of Aficamten. [PDF]

Clin Pharmacokinet
Xu D, Lutz JD, Divanji P, Li J, Benattia Y, Griffith A, Heitner SB, Kupfer S, German P.   +8 more
europepmc   +1 more source

Emerging Pharmacological and Invasive Therapies for Hypertrophic Cardiomyopathy with Obstructive Physiology. [PDF]

Card Fail Rev
Li-Wen Chu E, Seung Kim D, Masri A.
europepmc   +1 more source

Comparison of Diastolic Function Parameters After Alcohol Septal Ablation and Mavacamten Therapy in Obstructive Hypertrophic Cardiomyopathy. [PDF]

J Cardiovasc Dev Dis
Saleh D, Kim EY, Hussain K, Samhan A, Shi M, Meng Z, Schormann E, Bindra P, Cheema B, Fullenkamp DE, Baldridge AS, Puthumana JJ, Rigolin VH, Cremer PC, Flaherty JD, Choudhury L.   +15 more
europepmc   +1 more source